



Capital BlueCross is an Independent Licensee
of the BlueCross BlueShield Association

2020 Opioids Quantity Limit ER and IR

Transmucosal Immediate Release Fentanyl (TIRF) Quantity Limit

QUANTITY LEVEL LIMITS

Brand (generic)	Quantity Limit
Abstral® (fentanyl sublingual tablet)	
100 mcg tablet	120 tablets/30 days
200 mcg tablet	120 tablets/30 days
300 mcg tablet	120 tablets/30 days
400 mcg tablet	120 tablets/30 days
600 mcg tablet	120 tablets/30 days
800 mcg tablet	120 tablets/30 days
Actiq® (fentanyl lozenge) ^a	
200 mcg lozenge	120 tablets/30 days
400 mcg lozenge	120 tablets/30 days
600 mcg lozenge	120 tablets/30 days
800 mcg lozenge	120 tablets/30 days
1200 mcg lozenge	120 tablets/30 days
1600 mcg lozenge	120 tablets/30 days
Fentora® (fentanyl buccal tablet)	
100 mcg tablet	120 tablets/30 days
200 mcg tablet	120 tablets/30 days
400 mcg tablet	120 tablets/30 days
600 mcg tablet	120 tablets/30 days
800 mcg tablet	120 tablets/30 days
Lazanda® (fentanyl nasal spray)	
100 mcg/spray	30 bottles/30 days

1. Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies. Capital BlueCross is committed to operating in compliance with all applicable federal, state, and local laws and regulations. This Policy and Procedure has been reviewed for compliance with 45 CFR 156.122, 45 CFR 156.122 (a) (1) and (2), and 45 CFR 156.122(c).

Brand (generic)	Quantity Limit
300 mcg/spray	30 bottles/30 days
400 mcg/spray	30 bottles/30 days
Subsys™ (fentanyl sublingual spray)	
100 mcg spray	120 sprays/30 days
200 mcg spray	120 sprays/30 days
400 mcg spray	120 sprays/30 days
600 mcg spray	120 sprays/30 days
800 mcg spray	120 sprays/30 days
1200 mcg spray	240 sprays (120 dose packages of 2 x 600 mcg sprays)/30 days
1600 mcg spray	240 sprays (120 dose packages of 2 x 800 mcg sprays)/30 days

a – generic fentanyl citrate lozenge included in program

1. Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies. Capital BlueCross is committed to operating in compliance with all applicable federal, state, and local laws and regulations. This Policy and Procedure has been reviewed for compliance with 45 CFR 156.122, 45 CFR 156.122 (a) (1) and (2), and 45 CFR 156.122(c).

EXTENDED RELEASE OPIOIDS (QUANTITY LIMIT RECOMMENDED LIMITS)

Brand (generic)	Quantity Limit Per 30 Days
Narcotic Analgesics	
Arymo ER (morphine sulfate)	
15 mg extended release tablet	60 tablets/month
30 mg extended release tablet	30 tablets/month
60 mg extended release tablet	0 tablets/month
Belbuca (buprenorphine buccal film)	
75 mcg buccal film	60 films/month
150 mcg buccal film	60 films/month
300 mcg buccal film	60 films/month
450 mcg buccal film	60 films/month
600 mcg buccal film	60 films/month
750 mcg buccal film	60 films/month
900 mcg buccal film	30 films/month
Butrans, Buprenorphine Transdermal System	
5 mcg/hour transdermal system ^a	4 systems/month
7.5 mcg/hour transdermal system	4 systems/month
10 mcg/hour transdermal system ^a	4 systems/month
15 mcg/hour transdermal system ^a	4 systems/month
20 mcg/hour transdermal system ^a	4 systems/month
Duragesic (fentanyl transdermal patch)	
12 mcg/hr transdermal patch ^a	10 patches/month
25 mcg/hr transdermal patch ^a	0 patches/month
50 mcg/hr transdermal patch ^a	0 patches/month
75 mcg/hr transdermal patch ^a	0 patches/month

a – generic available, included in quantity limit program

1. Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies. Capital BlueCross is committed to operating in compliance with all applicable federal, state, and local laws and regulations. This Policy and Procedure has been reviewed for compliance with 45 CFR 156.122, 45 CFR 156.122 (a) (1) and (2), and 45 CFR 156.122(c).

Brand (generic)	Quantity Limit Per 30 Days
100 mcg/hr transdermal patch ^a	0 patches/month
Embeda (morphine/naltrexone ER)	
20 mg/0.8 mg controlled-release capsule	30 capsules/month
30 mg/1.2 mg controlled-release capsule	30 capsules/month
50 mg/2 mg controlled-release capsule	30 capsules/month
60 mg/2.4 mg controlled-release capsule	0 capsules/month
80 mg/3.2 mg controlled-release capsule	0 capsules/month
100 mg/4 mg controlled-release capsule	0 capsules/month
Exalgo (hydromorphone ER)	
8 mg extended-release tablet ^a	30 tablets/month
12 mg extended-release tablet ^a	30 tablets/month
16 mg extended-release tablet ^a	0 tablets
32 mg extended-release tablet ^a	0 tablets
fentanyl transdermal patch	
37.5 mcg/hr transdermal patch ^a	0 patches/month
62.5 mcg/hr transdermal patch ^a	0 patches/month
87.5 mcg/hr transdermal patch ^a	0 patches/month
Hysingla ER (hydrocodone ER)	
20 mg extended-release tablet	30 tablets/30 days
30 mg extended-release tablet	30 tablets/30 days
40 mg extended-release tablet	30 tablets/30 days
60 mg extended-release tablet	0 tablets/30 days
80 mg extended-release tablet	0 tablets/30 days
100 mg extended-release tablet	0 tablets/30 days

a – generic available, included in quantity limit program

1. Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies. Capital BlueCross is committed to operating in compliance with all applicable federal, state, and local laws and regulations. This Policy and Procedure has been reviewed for compliance with 45 CFR 156.122, 45 CFR 156.122 (a) (1) and (2), and 45 CFR 156.122(c).

Brand (generic)	Quantity Limit Per 30 Days
120 mg extended-release tablet	0 tablets/30 days
Kadian (morphine sulfate ER)	
10 mg sustained-release capsule ^a	30 capsules/30 days
20 mg sustained-release capsule ^a	30 capsules/30 days
30 mg sustained-release capsule ^a	30 capsules/30 days
40 mg sustained-release capsule ^a	30 capsules/30 days
50 mg sustained-release capsule ^a	30 capsules/30 days
60 mg sustained-release capsule ^a	0 capsules/30 days
70 mg sustained-release capsule ^b	0 capsules/30 days
80 mg sustained-release capsule ^a	0 capsules/30 days
100 mg sustained-release capsule ^a	0 capsules/30 days
130 mg sustained-release capsule ^b	0 capsules/30 days
150 mg sustained-release capsule ^b	0 capsules/30 days
200 mg sustained-release capsule	0 capsules/30 days
Morphabond ER (morphine ER)	
15 mg ER tablet	60 tablets/30 days
30 mg ER tablet	30 tablets/30 days
60 mg ER tablet	0 tablets/30 days
100 mg ER tablet	0 tablets/30 days
Morphine Sulfate ER	
30 mg sustained-release capsule	30 capsules/30 days
45 mg sustained-release capsule	30 capsules/30 days
60 mg sustained-release capsule	0 capsules/30 days
75 mg sustained-release capsule	0 capsules/30 days

a – generic available, included in quantity limit program

1. Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies. Capital BlueCross is committed to operating in compliance with all applicable federal, state, and local laws and regulations. This Policy and Procedure has been reviewed for compliance with 45 CFR 156.122, 45 CFR 156.122 (a) (1) and (2), and 45 CFR 156.122(c).

Brand (generic)	Quantity Limit Per 30 Days
90 mg sustained-release capsule	0 capsules/30 days
120 mg sustained-release capsule	0 capsules/30 days
MS Contin (morphine sulfate ER)	
15 mg sustained-release tablet ^a	60 tablets/30 days
30 mg sustained-release tablet ^a	30 tablets/30 days
60 mg sustained-release tablet ^a	0 tablets/30 days
100 mg sustained-release tablet ^a	0 tablets/30 days
200 mg sustained-release tablet ^a	0 tablets/30 days
Opana ER (oxymorphone SR, crush resistant ER)	
5 mg sustained-release tablet	60 tablets/30 days
7.5 mg sustained-release tablet	60 tablets/30 days
10 mg sustained-release tablet	30 tablets/30 days
15 mg sustained-release tablet	30 tablets/30 days
20 mg sustained-release tablet	0 tablets/30 days
30 mg sustained-release tablet	0 tablets/30 days
40 mg sustained-release tablet	0 tablets/30 days
OxyContin (oxycodone ER)	
5 mg extended release tablet ^b	60 tablets/30 days
10 mg extended release tablet	60 tablets/30 days
15 mg extended release tablet	60 tablets/30 days
20 mg extended release tablet	30 tablets/30 days
30 mg extended release tablet	30 tablets/30 days
40 mg extended release tablet	0 tablets/30 days
60 mg extended release tablet	0 tablets/30 days

a – generic available, included in quantity limit program

1. Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies. Capital BlueCross is committed to operating in compliance with all applicable federal, state, and local laws and regulations. This Policy and Procedure has been reviewed for compliance with 45 CFR 156.122, 45 CFR 156.122 (a) (1) and (2), and 45 CFR 156.122(c).

Brand (generic)	Quantity Limit Per 30 Days
80 mg extended release tablet	0 tablets/30 days
Oxymorphone SR	
5 mg sustained-release tablet	60 tablets/30 days
7.5 mg sustained-release tablet	60 tablets/30 days
10 mg sustained-release tablet	30 tablets/30 days
15 mg sustained-release tablet	30 tablets/30 days
20 mg sustained-release tablet	0 tablets/30 days
30 mg sustained-release tablet	0 tablets/30 days
40 mg sustained-release tablet	0 tablets/30 days
Xtampza ER (oxycodone ER)	
9 mg capsule	60 capsules/30 days
13.5 mg capsule	60 capsules/30 days
18 mg capsule	30 capsules/30 days
27 mg capsule	30 capsules/30 days
36 mg capsule	0 capsules/30 days
Zohydro ER Abuse Deterrent (hydrocodone ER)	
10 mg sustained-release capsule	60 capsules/30 days
15 mg sustained-release capsule	60 capsules/30 days
20 mg sustained-release capsule	60 capsules/30 days
30 mg sustained-release capsule	30 capsules/30 days
40 mg sustained-release capsule	30 capsules/30 days
50 mg sustained-release capsule	30 capsules/30 days
Tramadol, Tapentadol	
ConZip (tramadol SR biphasic ER)	

a – generic available, included in quantity limit program

1. Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies. Capital BlueCross is committed to operating in compliance with all applicable federal, state, and local laws and regulations. This Policy and Procedure has been reviewed for compliance with 45 CFR 156.122, 45 CFR 156.122 (a) (1) and (2), and 45 CFR 156.122(c).

Brand (generic)	Quantity Limit Per 30 Days
100 mg sustained-release capsule	30 capsules/30 days
200 mg sustained-release capsule	30 capsules/30 days
300 mg sustained-release capsule	30 capsules/30 days
Nucynta ER (tapentadol ER)	
50 mg extended-release tablet	60 tablets/30 days
100 mg extended-release tablet	30 tablets/30 days
150 mg extended-release tablet	0 tablets/30 days
200 mg extended-release tablet	0 tablets/30 days
250 mg extended-release tablet	0 tablets/30 days
tramadol ER	
100 mg sustained-release tablet ^a	30 tablets/30 days
200 mg sustained-release tablet ^a	30 tablets/30 days
300 mg sustained-release tablet ^a	30 tablets/30 days
Tramadol ER (tramadol SR biphasic)	
150 mg sustained-release capsule	30 capsules/30 days
Ultram ER (tramadol ER)	
100 mg sustained-release tablet ^a	30 tablets/30 days
200 mg sustained-release tablet ^a	30 tablets/30 days
300 mg sustained-release tablet ^a	30 tablets/30 days

a – generic available, included in quantity limit program

1. Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies. Capital BlueCross is committed to operating in compliance with all applicable federal, state, and local laws and regulations. This Policy and Procedure has been reviewed for compliance with 45 CFR 156.122, 45 CFR 156.122 (a) (1) and (2), and 45 CFR 156.122(c).

Agent	Quantity Limit
Dolophine (methadone)^a	
5 mg tablet	60 tablets/30 days
10 mg tablet	30 tablets/30 days
methadone^a	
5 mg/5mL solution	300 mL/30 days
10 mg/5 mL solution	150 mL/30 days

a – generic available, included in quantity limit program

IMMEDIATE RELEASE OPIOIDS (QUANTITY LIMIT RECOMMENDED LIMITS)

Single Ingredient Agents	Strength	Quantity Limit - Child	Quantity Limit - Adult
butorphanol ^a	10 mg/mL nasal spray	0 mL/30 days	2.5 mL (1 bottle)/30 days
Codeine	15 mg tablet	18 tablets/30 days	30 tablets/30 days
Codeine ^a	30 mg tablet	18 tablets/30 days	30 tablets/30 days
Codeine	60 mg tablet	15 tablets/30 days	25 tablets/30 days
Dilaudid (hydromorphone) ^a	2 mg tablet	18 tablets/30 days	30 tablets/30 days
Dilaudid (hydromorphone) ^a	4 mg tablet	9 tablets/30 days	15 tablets/30 days
Dilaudid (hydromorphone) ^a	8 mg tablet	3 tablets/30 days	5 tablets/30 days
Dilaudid (hydromorphone) ^a	1 mg/mL liquid	36 mL/30 days	60 mL/30 days
Levorphanol ^a	2 mg tablet	6 tablets/30 days	10 tablets/30 days
Levorphanol	3 mg tablet	6 tablets/30 days	10 tablets/30 days
Meperidine	50 mg tablet	30 tablets/30 days	30 tablets/30 days
Meperidine	100 mg tablet	15 tablets/30 days	15 tablets/30 days
Meperidine	50 mg/5 mL solution	150 mL/30 days	150 mL/30 days
Morphine ^a	15 mg tablet	9 tablets/30 days	15 tablets/30 days
Morphine ^a	30 mg tablet	3 tablets/30 days	5 tablets/30 days
Morphine ^a	10 mg/5 mL solution	75 mL/30 days	125 mL/30 days
Morphine ^a	20 mg/5 mL solution	36 mL/30 days	60 mL/30 days

a – generic available, included in quantity limit program

1. Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies. Capital BlueCross is committed to operating in compliance with all applicable federal, state, and local laws and regulations. This Policy and Procedure has been reviewed for compliance with 45 CFR 156.122, 45 CFR 156.122 (a) (1) and (2), and 45 CFR 156.122(c).

Single Ingredient Agents	Strength	Quantity Limit - Child	Quantity Limit - Adult
Morphine ^a	20 mg/mL concentrate	6 mL/30 days	10 mL/30 days
oxycodone ^a	5 mg capsule	18 capsules/30 days	30 capsules/30 days
Oxaydo, Roxybond (oxycodone)	5 mg tablet	18 tablets/30 days	30 tablets/30 days
Oxaydo (oxycodone)	7.5 mg tablet	12 tablets/30 days	20 tablets/30 days
oxycodone ^a	10 mg tablet	9 tablets/30 days	15 tablets/30 days
oxycodone ^a	20 mg tablet	3 tablets/30 days	5 tablets/30 days
oxycodone ^a	5 mg/5mL solution	99 mL/30 days	165 mL/30 days
oxycodone ^a	20 mg/mL concentrate	3 mL/30 days	5 mL/30 days
Roxicodone (oxycodone) ^a	5 mg tablet	18 tablets/30 days	30 tablets/30 days
Roxicodone (oxycodone) ^a	15 mg tablet	6 tablets/30 days	10 tablets/30 days
Roxybond (oxycodone)	15 mg tablet	6 tablets/30 days	10 tablets/30 days
Roxybond (oxycodone)	30 mg tablet	3 tablets/30 days	5 tablets/30 days
Roxicodone (oxycodone) ^a	30 mg tablet	3 tablets/30 days	5 tablets/30 days
Opana (oxymorphone) ^a	5 mg tablet	9 tablets/30 days	15 tablets/30 days
Opana (oxymorphone) ^a	10 mg tablet	3 tablets/30 days	5 tablets/30 days
Nucynta (tapentadol)	50 mg tablet	6 tablets/30 days	10 tablets/30 days
Nucynta (tapentadol)	75 mg tablet	3 tablets/30 days	5 tablets/30 days
Nucynta (tapentadol)	100 mg tablet	3 tablets/30 days	5 tablets/30 days
Ultram (tramadol) ^a	50 mg tablet	30 tablets/30 days	50 tablets/30 days

a – generic available, included in quantity limit program

1. Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies. Capital BlueCross is committed to operating in compliance with all applicable federal, state, and local laws and regulations. This Policy and Procedure has been reviewed for compliance with 45 CFR 156.122, 45 CFR 156.122 (a) (1) and (2), and 45 CFR 156.122(c).

Combination Ingredient Agents	Strength	Quantity Limit - Child	Quantity Limit - Adult
Oxycodone/Ibuprofen	5 mg/400 mg tablet	12 tablets/30 days	20 tablets/30 days
Reprexain (hydrocodone/ibuprofen) ^a	2.5 mg/200 mg tablet	15 tablets/30 days	25 tablets/30 days
Reprexain, Ibudone (hydrocodone/ibuprofen) ^a	5 mg/200 mg tablet	15 tablets/30 days	25 tablets/30 days
Reprexain, Ibudone, Xylon (hydrocodone/ibuprofen) ^a	10 mg/200 mg tablet	15 tablets/30 days	25 tablets/30 days
Vicoprofen (hydrocodone/ibuprofen) ^a	7.5 mg/200 mg tablet	15 tablets/30 days	25 tablets/30 days
Ultracet (tramadol/acetaminophen) ^a	37.5 mg/325 mg tablet	24 tablets/30 days	40 tablets/30 days
oxycodone/aspirin ^a	4.8355 mg/325 mg tablet	18 tablets/30 days	30 tablets/30 days
Synalgos-DC, Aspirin/Caffeine/Dihydrocodeine	356.4 mg/30 mg/16 mg capsule	30 capsules/30 days	50 capsules/30 days
Apadaz (benzhydrocodone/acetaminophen)	4.08/325 mg tablet	30 tablets/30 days	50 tablets/30 days
Apadaz (benzhydrocodone/acetaminophen)	6.12/325 mg tablet	24 tablets/30 days	40 tablets/30 days
Apadaz (benzhydrocodone/acetaminophen)	8.16/325 mg tablet	18 tablets/30 days	30 tablets/30 days
Percocet, Endocet (oxycodone/acetaminophen) ^a	2.5 mg/325 mg tablet	36 tablets/30 days	60 tablets/30 days
Percocet, Endocet, Roxicet (oxycodone/acetaminophen) ^a	5 mg/325 mg tablet	18 tablets/30 days	30 tablets/30 days
Percocet, Endocet (oxycodone/acetaminophen) ^a	7.5 mg/325 mg tablet	12 tablets/30 days	20 tablets/30 days

a – generic available, included in quantity limit program

1. Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies. Capital BlueCross is committed to operating in compliance with all applicable federal, state, and local laws and regulations. This Policy and Procedure has been reviewed for compliance with 45 CFR 156.122, 45 CFR 156.122 (a) (1) and (2), and 45 CFR 156.122(c).

Combination Ingredient Agents	Strength	Quantity Limit - Child	Quantity Limit - Adult
Percocet, Endocet (oxycodone/acetaminophen) ^a	10 mg/325 mg tablet	9 tablets/30 days	15 tablets/30 days
Nalocet (oxycodone/acetaminophen)	2.5 mg/300 mg tablet	36 tablets/30 days	60 tablets/30 days
Primlev (oxycodone/acetaminophen)	5 mg/300 mg tablet	18 tablets/30 days	30 tablets/30 days
Primlev (oxycodone/acetaminophen)	7.5 mg/300 mg tablet	12 tablets/30 days	20 tablets/30 days
Primlev (oxycodone/acetaminophen)	10 mg/300 mg tablet	9 tablets/30 days	15 tablets/30 days
Roxicet (oxycodone/acetaminophen)	5 mg/325 mg/5 mL solution	60 mL/30 days	100 mL/30 days
Acetaminophen/Codeine ^a	120 mg/12 mg/5 mL solution	270 mL/30 days	450 mL/30 days
Tylenol w/Codeine (acetaminophen/codeine) ^a	300 mg/15 mg tablet	18 tablets/30 days	30 tablets/30 days
Tylenol w/Codeine (acetaminophen/codeine) ^a	300 mg/30 mg tablet	18 tablets/30 days	30 tablets/30 days
Tylenol w/Codeine (acetaminophen/codeine) ^a	300 mg/60 mg tablet	15 tablets/30 days	25 tablets/30 days
Hycet (hydrocodone/acetaminophen) ^a	7.5 mg/325 mg/15 mL solution	270 mL/30 days	450 mL/30 days
Hydrocodone/Acetaminophen ^a	2.5 mg/325 mg tablet	36 tablets/30 days	60 tablets/30 days
Norco (hydrocodone/acetaminophen) ^a	5 mg/325 mg tablet	24 tablets/30 days	40 tablets/30 days
Norco (hydrocodone/acetaminophen) ^a	7.5 mg/325 mg tablet	18 tablets/30 days	30 tablets/30 days
Norco (hydrocodone/acetaminophen) ^a	10 mg/325 mg tablet	15 tablets/30 days	25 tablets/30 days

a – generic available, included in quantity limit program

1. Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies. Capital BlueCross is committed to operating in compliance with all applicable federal, state, and local laws and regulations. This Policy and Procedure has been reviewed for compliance with 45 CFR 156.122, 45 CFR 156.122 (a) (1) and (2), and 45 CFR 156.122(c).

Combination Ingredient Agents	Strength	Quantity Limit - Child	Quantity Limit - Adult
Xodol (hydrocodone/acetaminophen) ^a	5 mg/300 mg tablet	24 tablets/30 days	40 tablets/30 days
Xodol (hydrocodone/acetaminophen) ^a	7.5 mg/300 mg tablet	18 tablets/30 days	30 tablets/30 days
Xodol (hydrocodone/acetaminophen) ^a	10 mg/300 mg tablet	15 tablets/30 days	25 tablets/30 days
hydrocodone/acetaminophen solution	10 mg/325 mg/15 mL solution	225 mL/30 days	375 mL/30 days
Zolvit/Lortab (hydrocodone/acetaminophen)	10 mg/300 mg/15 mL solution	203 mL/30 days	338 mL/30 days
Trezix (acetaminophen/caffeine/dihydrocodeine)	320.5 mg/30 mg/16 mg capsule	30 capsules/30 days	50 capsules/30 days
Acetaminophen/Caffeine/Dihydrocodeine ^a	325 mg/30 mg/16 mg tablet	30 tablets/30 days	50 tablets/30 days
pentazocine/naloxone ^a	50 mg/0.5 mg tablet	6 tablets/30 days	10 tablets/30 days

a – generic available, included in quantity limit program

Benefit Determination

The existence of this pharmacy policy does not mean that this service is a covered benefit under the member's contract. Benefit determinations should be based in all cases on the applicable contract language. Pharmacy policies do not constitute a description of benefits. A member's individual or group customer benefits govern which pharmaceuticals are covered, which are excluded, and which are subject to benefit limits and which require authorization. Members and providers should consult the member's benefit information or contact Capital BlueCross for benefit information.

1. Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies. Capital BlueCross is committed to operating in compliance with all applicable federal, state, and local laws and regulations. This Policy and Procedure has been reviewed for compliance with 45 CFR 156.122, 45 CFR 156.122 (a) (1) and (2), and 45 CFR 156.122(c).

Disclaimer

Capital's pharmacy policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any pharmacy policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this pharmacy policy and to member's benefit information, the benefit information will govern. Capital BlueCross considers the information contained in this pharmacy policy to be proprietary and it may only be disseminated as permitted by law.

1. Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies. Capital BlueCross is committed to operating in compliance with all applicable federal, state, and local laws and regulations. This Policy and Procedure has been reviewed for compliance with 45 CFR 156.122, 45 CFR 156.122 (a) (1) and (2), and 45 CFR 156.122(c).